Navinci Featured in BioStock
Navinci has been featured in an article by BioStock highlighting the company’s unique technology and future ambitions.
Professor Joakim Lundeberg Joins Navinci’s Board of Directors
Professor Joakim Lundeberg, a world-leading expert in molecular biotechnology and spatial biology, has joined Navinci’s Board of Directors.
Navinci Launches Naveni® Plex Omni Service Providing Expert-Led Access to Spatial Interactomics
Navinci is proud to announce the launch of the Naveni® Plex Omni Service, giving researchers access to cutting edge multiplex isPLA technology.
Announcing the Winners of the Spatial Interactomics Grant 2025
Navinci is pleased to announce the winners of the Spatial Interactomics Grant 2025
Vector Laboratories Launches Glysite™ Explorer in situ PLA Glycan Detection Kit to Advance Functional Proteomics Research
Vector Laboratories Launches Glysite™ Explorer in situ PLA Glycan Detection Kit to Advance Functional Proteomics Research
Navinci Secures €5.3 Million in Funding from Existing Owners and a Strategic Investment from Jonathan Milner at Meltwind
The funds will be used to accelerate product development, strengthen operations, and position the company for its next phase of growth.
Spatial Interactomics Grant 2025
Navinci is proud to announce the launch of the 2025 Spatial Interactomics Grant Program, inviting researchers from across the globe to push the boundaries of proteomics and spatial biology.
Navinci Appoints Magnus Hurst as New Chief Financial Officer
Navinci is pleased to announce the appointment of Magnus Hurst as its Chief Financial Officer (CFO), marking the next phase of growth for the company.
Introducing Naveni® Plex
Navinci is proud to introduce Naveni® Plex, the first multiplex in situ proximity ligation assay, allowing for the simultaneous detection of three separate targets or protein-protein interactions.
New kits for Leica BOND RX/RXm with fluorescent readout
Leica Biosystems and Navinci collaborate to automate in situ proximity ligation assays, now with fluorescent readout.
Jenny Sundqvist appointed CEO of Navinci
Navinci’s Board of Directors is pleased to announce the appointment of Jenny Sundqvist as the new Chief Executive Officer, effective December 1, 2024.
Precision for Medicine and Navinci Announce Strategic Partnership
A partnership announced between Precision for Medicine and Navinci to offer isPLA as part of Precision for Medicine’s CRO services.